Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study

Published:January 14, 2020DOI:

      Background and Aims

      The treatment of submucosal (T1b) esophageal adenocarcinoma (EAC) remains in evolution, with some evidence supporting endoscopic management of low-risk lesions. Using a multicenter cohort, we evaluated outcomes of patients with T1b EAC and predictors of survival.


      Patients diagnosed between 2001 and 2016 with T1b EAC were identified from 3 academic medical centers in the United States. Demographic, clinical, and outcome data were collected. Outcomes studied were overall and cancer-free survival. Cox proportional hazards models were constructed to assess independent predictors of survival.


      One hundred forty-one patients were included, of whom 68 (48%) underwent esophagectomy and 73 (52%) were treated endoscopically. Most patients (85.8%) had high-risk histologic features. Thirty-day operative mortality was 2.9%. Median follow-up in the esophagectomy and endoscopic cohorts was 49.4 and 43.4 months, respectively. Patients treated endoscopically were older with higher comorbidity scores, with 46 (63%) achieving histologic remission. Nineteen patients (26.0%) also received chemoradiation. Five-year overall survival rates in the surgical and endoscopic cohorts were 89% and 59%, respectively, whereas 5-year cancer-free survival rates were 92% and 69%. Presence of high-risk histologic features was associated with reduced overall survival.


      In this large multicenter study of patients with T1b EAC, esophagectomy was associated with improved overall but not cancer-free survival. High-risk histologic features were associated with poorer survival.


      EAC (esophageal adenocarcinoma), LVI (lymphovascular invasion)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rustgi A.K.
        • El-Serag H.B.
        Esophageal carcinoma.
        N Engl J Med. 2014; 371: 2499-2509
        • Dunbar K.B.
        • Spechler S.J.
        The risk of lymph-node metastases in patients with high-grade dysplasia or intramucosal carcinoma in Barrett's esophagus: a systematic review.
        Am J Gastroenterol. 2012; 107: 850-862
        • Badreddine R.J.
        • Prasad G.A.
        • Lewis J.T.
        • et al.
        Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma.
        Clin Gastroenterol Hepatol. 2010; 8: 248-253
        • Watson T.J.
        Esophagectomy for superficial esophageal neoplasia.
        Gastrointest Endosc Clin North Am. 2017; 27: 531-546
        • Prasad G.A.
        • Wu T.T.
        • Wigle D.A.
        • et al.
        Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus.
        Gastroenterology. 2009; 137: 815-823
        • Markar S.R.
        • Karthikesalingam A.
        • Thrumurthy S.
        • Low D.E.
        Volume-outcome relationship in surgery for esophageal malignancy: systematic review and meta-analysis 2000-2011.
        J Gastrointest Surg. 2012; 16: 1055-1063
        • Manner H.
        • Pech O.
        • Heldmann Y.
        • et al.
        Efficacy, safety, and long-term results of endoscopic treatment for early stage adenocarcinoma of the esophagus with low-risk sm1 invasion.
        Clin Gastroenterol Hepatol. 2013; 11: 630-635
        • Ballard D.D.
        • Choksi N.
        • Lin J.
        • et al.
        Outcomes of submucosal (T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection.
        World J Gastrointest Endosc. 2016; 8: 763-769
        • Schwameis K.
        • Green K.M.
        • Worrell S.G.
        • et al.
        Outcome with primary en-bloc esophagectomy for submucosal esophageal adenocarcinoma.
        Ann Surg Oncol. 2017; 24: 3921-3925
        • Boys J.A.
        • Worrell S.G.
        • Chandrasoma P.
        • et al.
        Can the risk of lymph node metastases be gauged in endoscopically resected submucosal esophageal adenocarcinomas? A multi-center study.
        J Gastrointest Surg. 2016; 20: 6-12
        • Blevins C.H.
        • Iyer P.G.
        Endoscopic therapy for Barrett's oesophagus.
        Best Pract Res Clin Gastroenterol. 2015; 29: 167-177
        • Min Y.W.
        • Lee H.
        • Song B.G.
        • et al.
        Comparison of endoscopic submucosal dissection and surgery for superficial esophageal squamous cell carcinoma: a propensity score-matched analysis.
        Gastrointest Endosc. 2018; 88: 624-633
        • Weusten B.
        • Bisschops R.
        • Coron E.
        • et al.
        Endoscopic management of Barrett's esophagus: European Society of Gastrointestinal Endoscopy (ESGE) position statement.
        Endoscopy. 2017; 49: 191-198
        • Chu J.N.
        • Choi J.
        • Tramontano A.
        • et al.
        Surgical vs endoscopic management of T1 esophageal adenocarcinoma: a modeling decision analysis.
        Clin Gastroenterol Hepatol. 2018 Mar; 16: 392-400.e7
        • Shaheen N.J.
        • Falk G.W.
        • Iyer P.G.
        • et al.
        ACG clinical guideline: diagnosis and management of Barrett's esophagus.
        Am J Gastroenterol. 2016; 111: 30-50
        • Leggett C.L.
        • Lewis J.T.
        • Wu T.T.
        • et al.
        Clinical and histologic determinants of mortality for patients with Barrett's esophagus-related T1 esophageal adenocarcinoma.
        Clin Gastroenterol Hepatol. 2015; 13: 653-658
        • Namasivayam V.
        • Wang K.K.
        • Prasad G.A.
        Endoscopic mucosal resection in the management of esophageal neoplasia: current status and future directions.
        Clin Gastroenterol Hepatol. 2010; 8 (quiz e796): 743-754
        • Charlson M.E.
        • Pompei P.
        • Ales K.L.
        • et al.
        A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.
        J Chronic Dis. 1987; 40: 373-383
        • Ishihara R.
        • Oyama T.
        • Abe S.
        • et al.
        Risk of metastasis in adenocarcinoma of the esophagus: a multicenter retrospective study in a Japanese population.
        J Gastroenterol. 2017; 52: 800-808
        • Schölvinck D.
        • Künzli H.
        • Meijer S.
        • et al.
        Management of patients with T1b esophageal adenocarcinoma: a retrospective cohort study on patient management and risk of metastatic disease.
        Surg Endosc. 2016; 30: 4102-4113
        • Kunzli H.T.
        • Belghazi K.
        • Pouw R.E.
        • et al.
        Endoscopic management and follow-up of patients with a submucosal esophageal adenocarcinoma.
        United Eur Gastroenterol J. 2018; 6: 669-677
        • Manner H.
        • Pech O.
        • Heldmann Y.
        • et al.
        The frequency of lymph node metastasis in early-stage adenocarcinoma of the esophagus with incipient submucosal invasion (pT1b sm1) depending on histological risk patterns.
        Surg Endosc. 2015; 29: 1888-1896
        • Alvarez Herrero L.
        • Pouw R.
        • van Vilsteren F.
        • et al.
        Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens.
        Endoscopy. 2010; 42: 1030-1036
        • Leers J.M.
        • DeMeester S.R.
        • Oezcelik A.
        • et al.
        The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma.
        Ann Surg. 2011; 253: 271-278
        • Gotink A.W.
        • Ten Kate F.J.
        • Doukas M.
        • et al.
        Do pathologists agree with each other on the histological assessment of pT1b oesophageal adenocarcinoma?.
        United Eur Gastroenterol J. 2019; 7: 261-269

      Linked Article

      • Esophagectomy versus endoscopic resection for T1b esophageal adenocarcinoma: Depth matters!
        Gastrointestinal EndoscopyVol. 92Issue 5
        • Preview
          We read with great interest the article by Otaki and Ma,1 which retrospectively compared the outcomes of surgical resection (SR) versus endoscopic resection (ER) in 141 patients with T1b esophageal adenocarcinoma (EAC).1 The authors report a significantly higher overall survival in the SR group. Besides older age and comorbidities, a positive deep margin was an independent predictor of survival. There is little disagreement that ER alone is insufficient for medically fit patients with deep submucosal invasion (T1bSM2-3), lymphovascular invasion, or poor differentiation.
        • Full-Text
        • PDF
      • What to do with our T1b esophageal adenocarcinoma patients?
        Gastrointestinal EndoscopyVol. 92Issue 1
        • Preview
          After radical endoscopic resection of T1b esophageal adenocarcinoma (EAC), should I refer the patient for invasive esophagectomy to improve tumor-free survival? This question is preying on more and more endoscopists’ minds, now that more data are available illustrating that the risk of lymph node metastases associated with T1b EAC is lower than was generally assumed on the basis of old, mainly surgical, literature.1-4
        • Full-Text
        • PDF
      • When less is just less: endoscopic therapy for submucosal T1b esophageal cancer
        Gastrointestinal EndoscopyVol. 92Issue 1
        • Preview
          The introduction of techniques for EMR has enabled accurate pathologic staging of superficial esophageal cancer and definitive management of the disease in appropriate patients. Clear guidelines for endoscopic resection include the importance of resecting all visible nodules or lesions within a columnar-lined esophagus, resecting below the band when using the cap and band technique, and resecting all the submucosa down to the muscularis propria to accurately determine the depth of invasion and to minimize the risk of a positive deep resection margin in patients with submucosal tumor invasion.
        • Full-Text
        • PDF